Andrew Evens, DO, MBA, FACP, Rutgers University, New Brunswick, NJ, discusses the results from an analysis of older patients with Hodgkin lymphoma (HL) treated with brentuximab vedotin in the ECHELON-1 trial (NCT01712490), highlighting the higher efficacy of A+AVD compared to ABVD. Dr Evens mentions the tolerability results, both fatal and discrete, and refers to the S-1826 North American advanced stage study (NCT03907488). This interview took place at The 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
xGrant/Research Support: ORIEN and Leukemia & Lymphoma Society, Advisory Board (Research Related): Seattle Genetics, Hutchmed, Incyte, Daiichi Sankyo, and Epizyme Consultant (Educational Related): Research to Practice, Curio, Cota, Patient Power, Curio Science, and OncLive Consultant (Data and Safety Monitoring Board): Novartis, Abbvie, and Pharmacyclics